ClinicalTrials.gg
CompletedNCT03377699EXPECTUpdated Jan 20, 2023Results posted

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes

A Phase 3 interventional study of Insulin degludec and Insulin Aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 71 sites in 15 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. insulin degludec · Diabetes Mellitus, Type 1.

Enrollment
7th of 39
225 · median 38
Started
2017
with 2 others
Phase 3
7 of 39
none open now
Registered
32nd of 39
by date
Lead sponsor
30 of 39
Novo Nordisk A/S

Among the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing insulin degludec in Diabetes Mellitus, Type 1 as a file.
02

Study summary

The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use. In this study the medicine insulin degludec is compared to another medicine called insulin detemir. Participants will either get insulin degludec or insulin detemir and take it together with a medicine called insulin aspart - which treatment participants get is decided by chance. Participants will get pre-filled insulin pens. Participants will need to take blood sugar measurements several times a day. The study will last between 10 and 25 months depending on whether participants are already pregnant when they join the study. The number of visits and the tests ( for example blood and urine samples and ultrasound scans) the participants will have also depends on whether they are pregnant at study start.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 225 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Female, age at least 18 years at the time of signing - Diagnosed with type 1 diabetes mellitus for at least 1 year prior to the day of screening - Treated with multiple daily subcutaneous insulin injections or continuous subcutaneous insulin infusion (CSII) or inhaled insulin for at least 90 days prior to the day of screening - The subject is planning to become pregnant within 12 months from randomisation and willing to undertake pre-pregnancy counselling or the subject is pregnant with an intrauterine singleton living foetus (gestational week 8 to 13 (+6 days)) without any observed anomalies at randomisation, confirmed by an ultrasound scan - at screening below or equal to 8.0% (64 mmol/mol) by central laboratory Exclusion Criteria: - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening - Pregnant and having proteinuria as evaluated by urine protein-to-creatinine ratio above or equal to 300 mg/g in urine sample measured at screening - Subject being treated or became pregnant with assistance of in vitro fertilisation or other medical infertility treatment - Receipt of any concomitant medication in pregnancy according to local label within 28 days before screening and between screening and randomisation for non-pregnant subjects and 28 days before conception and between conception and randomisation for pregnant subjects - Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or pharmacologically dilated fundoscopy performed within the past 90 days prior to randomisation for non-pregnant subjects or within 28 days prior to randomisation for pregnant subjects. - History of severe hyperemesis gravidarum (requiring hospitalisation)

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Insulin Degludec

    Insulin Degludec once daily and Insulin Aspart 2-4 times daily

    Drug: Insulin degludec · Drug: Insulin Aspart

  • Active comparator
    Insulin Determir

    Insulin Determir once daily or twice daily and Insulin Aspart 2-4 times daily

    Drug: Insulin Aspart · Drug: Insulin detemir

Interventions

  • Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months

  • Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months

  • Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months

07

What researchers measure

Primary outcomes

  1. Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery

    Mean of the HbA1c data collected at gestational week (GW) corresponding to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact. On-treatment observation period started at the date of first dose of trial product and ended at the date of the last day on trial product, up to 22 months.

    Time frame: From GW 16 to GW 36

Secondary outcomes

  1. Number of Participants With HbA1c Below or Equal to 6.0% [42 Millimoles Per Mole (mmol/Mol)] From Last Planned HbA1c Prior to Delivery (Yes/no)

    Number of participants who achieved pre-defined HbA1c targets ≤ 6.0% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.0% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.0% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: From GW 16 to GW 36

  2. Number of Participants With HbA1c Below or Equal to 6.5% (48 mmol/Mol) From Last Planned HbA1c Prior to Delivery (Yes/no)

    Number of participants who achieved pre-defined HbA1c targets ≤ 6.5% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.5% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.5% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: From GW 16 to GW 36

  3. Last Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals)

    Mean of post-prandial glucose (PPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. Average PPG is defined as the average of the available blood glucouse (BG) measurements 90 minutes after breakfast, lunch and main evening meal respectively. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: From GW 16 to GW 36

  4. Last Planned Fasting Plasma Glucose Prior to Delivery

    Mean of fasting plasma glucose (FPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from in-trial observation period. The in-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: From GW 16 to GW 36

  5. Number of Hypoglycaemic Episodes During the Pregnancy Period

    Number of treatment emergent hypoglycaemic episodes during the pregnancy period is presented. Hypoglycaemic episode (plasma glucose \<= 3.9 mmol/L (70 milligrams per decilitre (mg/dL)) Or \> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode occurs on or after the first day of trial product administration, and no later than 7 days from the last day on trial product. The endpoint was evaluated based on the data from pregnancy period. Pregnancy period started from first day of pregnancy (date of conception corresponding to the first day in GW 2) or randomisation (whichever comes last) to the date of delivery.

    Time frame: From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)

  6. Number of Participants Who Developed Sight-threatening Retinopathy (Defined as Proliferative Retinopathy or Maculopathy) From Pregnancy Baseline to the End of Treatment (Yes/no)

    Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. Eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between pregnancy baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy.

    Time frame: From pregnancy baseline (corresponding to GW 8-13) to end of treatment (28 days after delivery)

  7. Number of Participants Who Developed Sight-threatening Retinopathy Defined as Proliferative Retinopathy or Maculopathy From Treatment Baseline to the End of Treatment (Yes/no)

    Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. For pregnant women, eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between treatment baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy.

    Time frame: From treatment baseline (week 0) to end of treatment (28 days after delivery)

  8. Number of Adverse Events During Pregnancy Period

    Number of adverse events (AEs) during pregnancy period is reported. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs presented are treatment-emergent AEs (TEAEs). The TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

    Time frame: From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)

  9. Number of Participants With Pre-eclampsia Defined as New-onset Hypertension Occurring From Gestational Week 20 to Delivery and Simultaneous Proteinuria or Presence of Eclampsia, HELLP Syndrome, or Other Severe Organ Involvement (Yes/no)

    Number of participants with one or more events of pre-eclampsia during pregnancy period is reported. Pre-eclampsia was defined as new-onset hypertension (greater than or equal to) ≥ 140 millimeters of mercury (mmHg) systolic or ≥ 90 mmHg diastolic, based on at least 2 measurements taken at least 4 hours apart) occurring from GW 20 to delivery and simultaneous proteinuria (defined as ≥ 300 mg protein in a 24 hours urine sample, a protein-to-creatinine ratio of ≥ 300 mg/g in a urine sample or a urine dipstick protein of 1+) or presence of eclampsia, haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, or other severe organ involvement. In the reported data, 'Yes' infers number of participants who had pre-eclampsia events whereas 'No' infers number of participants who have not had pre-eclampsia events.

    Time frame: From GW 20 to delivery

  10. Number of Participants With Different Modes of Delivery e.g. Vaginal, Operative Vaginal, Planned Caesarean Section or Unplanned Caesarean Section Delivery

    Number of participants who had delivered by which mode of delivery (vaginal, operative vaginal, planned caesarean section or unplanned caesarean section delivery) is presented. Planned caesarean section: decision taken \> 8 hours prior to delivery. Unplanned caesarean section: decision taken ≤ 8 hours prior to delivery. In case of 'early foetal death' or if the participant did not fill the pregnancy outcome form then mode of delivery was reported as 'missing'.

    Time frame: At birth

  11. Change in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery

    Change in body weight from pregnancy baseline to last planned visit prior to delivery is presented.

    Time frame: From pregnancy baseline (corresponding to gestational week 8-13) to last planned visit before delivery (last weight recording before given birth)

  12. Birth Weight for Live Birth Infants

    Mean birth weight for live birth infants is presented. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: At birth

  13. Birth Weight Standard Deviation (SD) Score for Live Birth Infants

    Mean of birth weight SD score for live infants is presented. Birth weight SD score indicates how far an infant's score deviates from the mean of the reference population of same age and same sex born at the same gestational week as per local normal curves. The SD score of 0 indicates that the infants born weigh approximately the same, negative score indicates that the infants born weigh lesser and positive score indicates that the infants born weigh more when compared with the reference population. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: At birth

  14. Number of Live Born Infants With Birth Weight < 10th Percentile for Gestational Age and Sex (Local References) (Yes/no)

    Number of live born infants with birth weight \<10th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants.In the reported data,'Yes' infers number of live born infants with birth weight \<10th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \<10th percentile for gestational age and sex.Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form.Endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion,up to 24 months.Date of trial completion:final scheduled follow-up visit (delivery + 58 days).

    Time frame: At birth

  15. Number of Live Born Infants With Birth Weight > 90th Percentile for Gestational Age and Sex (Local References) [Yes/no]

    Number of live born infants with birth weight \>90th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants. In the reported data,'Yes' infers number of live born infants with birth weight \>90th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \>90th percentile for gestational age and sex.Unaddressed category refers to cases where either parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if THE participants did not fill the pregnancy outcome form.The endpoint was evaluated based on the data from in-trial observation period:started at randomization and ended at the date of trial completion,up to 24 months. Date of trial completion:final scheduled follow-up visit (delivery + 58 days).

    Time frame: At birth

  16. Number of Participants With Pre-term Delivery

    Number of pregnant women who had pre-term delivery is presented. Pre-term delivery refers to delivery in \< 37 completed GWs. In the reported data, 'Yes' infers number of participants who had pre-term delivery whereas 'No' infers number of participants who has not had pre-term delivery. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion,up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery+58 days). For participants who had not attended the follow-up visit,the date of trial completion was the date of the last participant-investigator contact.

    Time frame: At birth

  17. Number of Participants With Early Foetal Death (Delivery Before 20 Completed GWs) (Yes/no)

    Number of participants who had early foetal death (delivery before 20 completed GWs) is presented. In the reported data, 'Yes' infers early foetal deaths whereas 'No' infers no foetal deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: At birth

  18. Number of Participants Who Had Perinatal Mortality (Death of Foetus/Infant ) (Yes/no)

    Number of participants who had foetal/infant loss at delivery is presented. Perinatal mortality: death of foetus/infant between ≥ 20 completed GWs before delivery and \<1 completed week after delivery). In the reported data, 'Yes' infers early foetal/infant deaths whereas 'No' infers no foetal/infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion, up to 24 months. Date of trial completion: final scheduled follow-up visit (delivery + 58 days).

    Time frame: Between at least 20 completed GWs before delivery and before 7 completed days after delivery

  19. Number of Participants Who Had Neonatal Mortality (Death of Infant) (Yes/no)

    Number of participants who had infant loss after delivery is presented. Neonatal mortality: death of infant between ≥7 completed days after delivery and \< 28 completed days after delivery. In the reported data, 'Yes' infers infant deaths whereas 'No' infers no infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: Between at least 7 completed days after delivery and before 28 completed days after delivery

  20. Number of Participants With Presence of Major Abnormalities (Classified According to European Concerted Action on Congenital Anomalies and Twins (EUROCAT)) in Their Foetus/Infants

    Number of participants who delivered foetuses/infants with abnormalities (classified according to EUROCAT) is presented. Presence of major abnormalities were based on adjudicated data, as after adjudication congenital anomalies were classified into major or minor anomalies or in other categories. In reported data, 'Yes' infers presence of major abnormalities whereas 'No' infers absence of major abnormalities in foetus/infant. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion up to 24 months. Date of trial completion : final scheduled follow-up visit (delivery + 58 days).

    Time frame: At birth

  21. Number of Participants With Live Born Infants (Yes/no)

    Number of participants with live born infants is presented. In the reported data, 'Yes' infers number of live infants whereas 'No' infers early foetal death or termination of pregnancy (induced/elective abortion). The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

    Time frame: At birth

  22. Number of Adverse Events in the Infant

    AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AEs in foetus/infant with particular focus on the AEs from delivery to follow-up are presented.

    Time frame: From delivery to final follow-up 30 days after delivery

  23. Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no)

    Number of infants with neonatal hypoglycaemic episodes is presented. Neonatal hypoglycaemic episodes defined as plasma glucose ≤ 1.7 mmol/L (31 mg/dL) during the first 24 hours after birth or below or equal to 2.5 mmol/L (45 mg/dl) between 24 hours and 48 hours after birth. In the reported data, 'Yes' infers number of infants with neonatal hypoglycaemic episodes whereas 'No' infers number of infants with no neonatal hypoglycaemic episodes. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form.

    Time frame: During between 24 and 48 hours after birth

08

Results

Posted Apr 27, 2022

Participant flow

The trial was conducted at 56 sites in 14 countries as follows (number of sites that screened participants/number of sites that randomised participants):Argentina (5/4); Australia (7/7); Austria (3/3); Brazil (6/6); Canada (6/5); Croatia (1/1); Denmark (2/2); Greece (3/3); Ireland (2/2); Israel (2/2); Italy (5/5); Russian Federation (8/8); Serbia (2/2) and United Kingdom (8/6).

Participant flow — Overall Study
MilestoneIDegIDet
Started111114
Treated110112
Saspregnant9194
Faspregnant9296
Completed8989
Not completed2225
Withdrew: Withdrawal by subject29
Withdrew: Lost to follow-up11
Withdrew: Commencement of medical infertility treatment during the course of the trial10
Withdrew: Non-pregnant subject initiating medication contraindicated during pregnancy11
Withdrew: Randomised non-pregnant did not become pregnant and withdrawn from trial118
Withdrew: Randomised non-pregnant did not become pregnant and not withdrawn from trial66

Outcome measures

PrimaryLast Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery

Mean of the HbA1c data collected at gestational week (GW) corresponding to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from both in-trial and on-treatment observation periods. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact. On-treatment observation period started at the date of first dose of trial product and ended at the date of the last day on trial product, up to 22 months.

Time frame:
From GW 16 to GW 36
Reported as:
Mean · Percentage glycosylated hemoglobin
Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery
Percentage glycosylated hemoglobinIDegIDet
in-trial6.30 ± 0.706.26 ± 0.73
on-treatment6.32 ± 0.696.26 ± 0.71
Statistical analysis
  • IDeg vs IDet · ANCOVA · p = <0.0001 · Mean treatment difference: -0.11 · 95% CI -0.31 to 0.08
  • IDeg vs IDet · ANCOVA · p = 0.3881 · Mean treatment difference: -0.08 · 95% CI -0.27 to 0.11
SecondaryNumber of Participants With HbA1c Below or Equal to 6.0% [42 Millimoles Per Mole (mmol/Mol)] From Last Planned HbA1c Prior to Delivery (Yes/no)

Number of participants who achieved pre-defined HbA1c targets ≤ 6.0% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.0% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.0% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
From GW 16 to GW 36
Reported as:
Count of participants · Participants
Number of Participants With HbA1c Below or Equal to 6.0% [42 Millimoles Per Mole (mmol/Mol)] From Last Planned HbA1c Prior to Delivery (Yes/no)
ParticipantsIDegIDet
Yes3631
No4853
SecondaryNumber of Participants With HbA1c Below or Equal to 6.5% (48 mmol/Mol) From Last Planned HbA1c Prior to Delivery (Yes/no)

Number of participants who achieved pre-defined HbA1c targets ≤ 6.5% prior to delivery after GW 16 is presented. In the reported data, 'Yes' infers number of participants who have achieved ≤ 6.5% HbA1c whereas 'No' infers number of participants who have not achieved ≤ 6.5% HbA1c. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
From GW 16 to GW 36
Reported as:
Count of participants · Participants
Number of Participants With HbA1c Below or Equal to 6.5% (48 mmol/Mol) From Last Planned HbA1c Prior to Delivery (Yes/no)
ParticipantsIDegIDet
Yes5853
No2631
SecondaryLast Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals)

Mean of post-prandial glucose (PPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. Average PPG is defined as the average of the available blood glucouse (BG) measurements 90 minutes after breakfast, lunch and main evening meal respectively. The endpoint was evaluated based on the data from in-trial observation period. In-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
From GW 16 to GW 36
Reported as:
Mean · mmol/L
Last Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals)
mmol/LIDegIDet
Last Planned Average Post-prandial Glucose Prior to Delivery (Average of Three Main Meals)7.37 ± 1.356.96 ± 1.63
SecondaryLast Planned Fasting Plasma Glucose Prior to Delivery

Mean of fasting plasma glucose (FPG) data collected from GW 16 to last planned visit prior to delivery is presented. This could be either GW 16, 20, 24, 28, 32, 36. The endpoint was evaluated based on the data from in-trial observation period. The in-trial observation period started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
From GW 16 to GW 36
Reported as:
Mean · mmol/L
Last Planned Fasting Plasma Glucose Prior to Delivery
mmol/LIDegIDet
Last Planned Fasting Plasma Glucose Prior to Delivery6.17 ± 2.056.79 ± 2.47
SecondaryNumber of Hypoglycaemic Episodes During the Pregnancy Period

Number of treatment emergent hypoglycaemic episodes during the pregnancy period is presented. Hypoglycaemic episode (plasma glucose \<= 3.9 mmol/L (70 milligrams per decilitre (mg/dL)) Or \> 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode occurs on or after the first day of trial product administration, and no later than 7 days from the last day on trial product. The endpoint was evaluated based on the data from pregnancy period. Pregnancy period started from first day of pregnancy (date of conception corresponding to the first day in GW 2) or randomisation (whichever comes last) to the date of delivery.

Time frame:
From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)
Reported as:
Number · Episodes
Number of Hypoglycaemic Episodes During the Pregnancy Period
EpisodesIDegIDet
Number of Hypoglycaemic Episodes During the Pregnancy Period54315982
SecondaryNumber of Participants Who Developed Sight-threatening Retinopathy (Defined as Proliferative Retinopathy or Maculopathy) From Pregnancy Baseline to the End of Treatment (Yes/no)

Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. Eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between pregnancy baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy.

Time frame:
From pregnancy baseline (corresponding to GW 8-13) to end of treatment (28 days after delivery)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Sight-threatening Retinopathy (Defined as Proliferative Retinopathy or Maculopathy) From Pregnancy Baseline to the End of Treatment (Yes/no)
ParticipantsIDegIDet
Left eye — Yes22
Left eye — No7979
Left eye — Missing1013
Right eye — Yes22
Right eye — No7979
Right eye — Missing1013
SecondaryNumber of Participants Who Developed Sight-threatening Retinopathy Defined as Proliferative Retinopathy or Maculopathy From Treatment Baseline to the End of Treatment (Yes/no)

Sight-threatening retinopathy is defined as proliferative retinopathy or maculopathy. For pregnant women, eye examination was performed by fundus photography or pharmacologically dilated fundoscopy to identify if participants have developed sight-threatening retinopathy. The number of participants who developed sight-threatening retinopathy between treatment baseline to the end of treatment is presented. In the reported data, 'Yes' infers number of participants who developed sight-threatening retinopathy whereas 'No' infers number of participants who have not developed sight-threatening retinopathy.

Time frame:
From treatment baseline (week 0) to end of treatment (28 days after delivery)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Sight-threatening Retinopathy Defined as Proliferative Retinopathy or Maculopathy From Treatment Baseline to the End of Treatment (Yes/no)
ParticipantsIDegIDet
Left eye — Yes22
Left eye — No7979
Left eye — Missing1013
Right eye — Yes22
Right eye — No7979
Right eye — Missing1013
SecondaryNumber of Adverse Events During Pregnancy Period

Number of adverse events (AEs) during pregnancy period is reported. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. All AEs presented are treatment-emergent AEs (TEAEs). The TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.

Time frame:
From the first day of pregnancy (date of conception) or randomisation to delivery (maximum 23 months)
Reported as:
Number · Events
Number of Adverse Events During Pregnancy Period
EventsIDegIDet
Number of Adverse Events During Pregnancy Period429328
SecondaryNumber of Participants With Pre-eclampsia Defined as New-onset Hypertension Occurring From Gestational Week 20 to Delivery and Simultaneous Proteinuria or Presence of Eclampsia, HELLP Syndrome, or Other Severe Organ Involvement (Yes/no)

Number of participants with one or more events of pre-eclampsia during pregnancy period is reported. Pre-eclampsia was defined as new-onset hypertension (greater than or equal to) ≥ 140 millimeters of mercury (mmHg) systolic or ≥ 90 mmHg diastolic, based on at least 2 measurements taken at least 4 hours apart) occurring from GW 20 to delivery and simultaneous proteinuria (defined as ≥ 300 mg protein in a 24 hours urine sample, a protein-to-creatinine ratio of ≥ 300 mg/g in a urine sample or a urine dipstick protein of 1+) or presence of eclampsia, haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, or other severe organ involvement. In the reported data, 'Yes' infers number of participants who had pre-eclampsia events whereas 'No' infers number of participants who have not had pre-eclampsia events.

Time frame:
From GW 20 to delivery
Reported as:
Count of participants · Participants
Number of Participants With Pre-eclampsia Defined as New-onset Hypertension Occurring From Gestational Week 20 to Delivery and Simultaneous Proteinuria or Presence of Eclampsia, HELLP Syndrome, or Other Severe Organ Involvement (Yes/no)
ParticipantsIDegIDet
Yes127
No7987
SecondaryNumber of Participants With Different Modes of Delivery e.g. Vaginal, Operative Vaginal, Planned Caesarean Section or Unplanned Caesarean Section Delivery

Number of participants who had delivered by which mode of delivery (vaginal, operative vaginal, planned caesarean section or unplanned caesarean section delivery) is presented. Planned caesarean section: decision taken \> 8 hours prior to delivery. Unplanned caesarean section: decision taken ≤ 8 hours prior to delivery. In case of 'early foetal death' or if the participant did not fill the pregnancy outcome form then mode of delivery was reported as 'missing'.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Participants With Different Modes of Delivery e.g. Vaginal, Operative Vaginal, Planned Caesarean Section or Unplanned Caesarean Section Delivery
ParticipantsIDegIDet
Spontaneous vaginal birth1118
Planned caesarean section4245
Operative vaginal birth89
Non planned caesarean section2315
Missing77
SecondaryChange in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery

Change in body weight from pregnancy baseline to last planned visit prior to delivery is presented.

Time frame:
From pregnancy baseline (corresponding to gestational week 8-13) to last planned visit before delivery (last weight recording before given birth)
Reported as:
Mean · Kilogram (Kg)
Change in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery
Kilogram (Kg)IDegIDet
Change in Body Weight From Pregnancy Baseline to Last Planned Visit Prior to Delivery11.97 ± 4.7910.81 ± 4.55
SecondaryBirth Weight for Live Birth Infants

Mean birth weight for live birth infants is presented. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
At birth
Reported as:
Mean · grams (g)
Birth Weight for Live Birth Infants
grams (g)IDegIDet
Birth Weight for Live Birth Infants3691.0 ± 628.013490.2 ± 629.94
SecondaryBirth Weight Standard Deviation (SD) Score for Live Birth Infants

Mean of birth weight SD score for live infants is presented. Birth weight SD score indicates how far an infant's score deviates from the mean of the reference population of same age and same sex born at the same gestational week as per local normal curves. The SD score of 0 indicates that the infants born weigh approximately the same, negative score indicates that the infants born weigh lesser and positive score indicates that the infants born weigh more when compared with the reference population. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
At birth
Reported as:
Mean · Standard Deviation score
Birth Weight Standard Deviation (SD) Score for Live Birth Infants
Standard Deviation scoreIDegIDet
Birth Weight Standard Deviation (SD) Score for Live Birth Infants1.7 ± 1.201.2 ± 1.22
SecondaryNumber of Live Born Infants With Birth Weight < 10th Percentile for Gestational Age and Sex (Local References) (Yes/no)

Number of live born infants with birth weight \<10th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants.In the reported data,'Yes' infers number of live born infants with birth weight \<10th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \<10th percentile for gestational age and sex.Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form.Endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion,up to 24 months.Date of trial completion:final scheduled follow-up visit (delivery + 58 days).

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Live Born Infants With Birth Weight < 10th Percentile for Gestational Age and Sex (Local References) (Yes/no)
ParticipantsIDegIDet
Yes13
No8481
Unaddressed11
SecondaryNumber of Live Born Infants With Birth Weight > 90th Percentile for Gestational Age and Sex (Local References) [Yes/no]

Number of live born infants with birth weight \>90th percentile for gestational age and sex is presented.It was assessed using local birth weight percentile curves.The unit of measure 'participants' infers number of live infants. In the reported data,'Yes' infers number of live born infants with birth weight \>90th percentile for gestational age and sex whereas 'No' infers number of live born infants birth weight is not \>90th percentile for gestational age and sex.Unaddressed category refers to cases where either parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if THE participants did not fill the pregnancy outcome form.The endpoint was evaluated based on the data from in-trial observation period:started at randomization and ended at the date of trial completion,up to 24 months. Date of trial completion:final scheduled follow-up visit (delivery + 58 days).

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Live Born Infants With Birth Weight > 90th Percentile for Gestational Age and Sex (Local References) [Yes/no]
ParticipantsIDegIDet
Yes5543
No3041
Unaddressed11
SecondaryNumber of Participants With Pre-term Delivery

Number of pregnant women who had pre-term delivery is presented. Pre-term delivery refers to delivery in \< 37 completed GWs. In the reported data, 'Yes' infers number of participants who had pre-term delivery whereas 'No' infers number of participants who has not had pre-term delivery. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion,up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery+58 days). For participants who had not attended the follow-up visit,the date of trial completion was the date of the last participant-investigator contact.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Participants With Pre-term Delivery
ParticipantsIDegIDet
Yes3426
No5766
Unaddressed14
SecondaryNumber of Participants With Early Foetal Death (Delivery Before 20 Completed GWs) (Yes/no)

Number of participants who had early foetal death (delivery before 20 completed GWs) is presented. In the reported data, 'Yes' infers early foetal deaths whereas 'No' infers no foetal deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Participants With Early Foetal Death (Delivery Before 20 Completed GWs) (Yes/no)
ParticipantsIDegIDet
Yes45
No8787
Unaddressed14
SecondaryNumber of Participants Who Had Perinatal Mortality (Death of Foetus/Infant ) (Yes/no)

Number of participants who had foetal/infant loss at delivery is presented. Perinatal mortality: death of foetus/infant between ≥ 20 completed GWs before delivery and \<1 completed week after delivery). In the reported data, 'Yes' infers early foetal/infant deaths whereas 'No' infers no foetal/infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion, up to 24 months. Date of trial completion: final scheduled follow-up visit (delivery + 58 days).

Time frame:
Between at least 20 completed GWs before delivery and before 7 completed days after delivery
Reported as:
Count of participants · Participants
Number of Participants Who Had Perinatal Mortality (Death of Foetus/Infant ) (Yes/no)
ParticipantsIDegIDet
Yes00
No9192
Unaddressed14
SecondaryNumber of Participants Who Had Neonatal Mortality (Death of Infant) (Yes/no)

Number of participants who had infant loss after delivery is presented. Neonatal mortality: death of infant between ≥7 completed days after delivery and \< 28 completed days after delivery. In the reported data, 'Yes' infers infant deaths whereas 'No' infers no infant deaths. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form. The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
Between at least 7 completed days after delivery and before 28 completed days after delivery
Reported as:
Count of participants · Participants
Number of Participants Who Had Neonatal Mortality (Death of Infant) (Yes/no)
ParticipantsIDegIDet
Yes00
No9192
Unaddressed14
SecondaryNumber of Participants With Presence of Major Abnormalities (Classified According to European Concerted Action on Congenital Anomalies and Twins (EUROCAT)) in Their Foetus/Infants

Number of participants who delivered foetuses/infants with abnormalities (classified according to EUROCAT) is presented. Presence of major abnormalities were based on adjudicated data, as after adjudication congenital anomalies were classified into major or minor anomalies or in other categories. In reported data, 'Yes' infers presence of major abnormalities whereas 'No' infers absence of major abnormalities in foetus/infant. The endpoint was evaluated based on the data from in-trial observation period: started at randomization and ended at the date of trial completion up to 24 months. Date of trial completion : final scheduled follow-up visit (delivery + 58 days).

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Participants With Presence of Major Abnormalities (Classified According to European Concerted Action on Congenital Anomalies and Twins (EUROCAT)) in Their Foetus/Infants
ParticipantsIDegIDet
Yes88
No8488
SecondaryNumber of Participants With Live Born Infants (Yes/no)

Number of participants with live born infants is presented. In the reported data, 'Yes' infers number of live infants whereas 'No' infers early foetal death or termination of pregnancy (induced/elective abortion). The endpoint was evaluated based on the data from in-trial observation period which started at randomization and ended at the date of trial completion, up to 24 months. The date of trial completion was the date of the final scheduled follow-up visit (delivery + 58 days). For participants who had not attended the follow-up visit, the date of trial completion was the date of the last participant-investigator contact.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Participants With Live Born Infants (Yes/no)
ParticipantsIDegIDet
Yes8685
No57
Unaddressed14
SecondaryNumber of Adverse Events in the Infant

AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product. AEs in foetus/infant with particular focus on the AEs from delivery to follow-up are presented.

Time frame:
From delivery to final follow-up 30 days after delivery
Reported as:
Number · Events
Number of Adverse Events in the Infant
EventsIDegIDet
Number of Adverse Events in the Infant164150
SecondaryNeonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no)

Number of infants with neonatal hypoglycaemic episodes is presented. Neonatal hypoglycaemic episodes defined as plasma glucose ≤ 1.7 mmol/L (31 mg/dL) during the first 24 hours after birth or below or equal to 2.5 mmol/L (45 mg/dl) between 24 hours and 48 hours after birth. In the reported data, 'Yes' infers number of infants with neonatal hypoglycaemic episodes whereas 'No' infers number of infants with no neonatal hypoglycaemic episodes. Unaddressed category refers to the cases where either the parents of the infant had not given consent to share information after delivery or the participants who were withdrawn from trial and they did not give any further information or if the participants did not fill the pregnancy outcome form.

Time frame:
During between 24 and 48 hours after birth
Reported as:
Count of participants · Participants
Neonatal Hypoglycaemic Episodes Defined as Plasma Glucose Below or Equal to 1.7 mmol/L (31 mg/dL) or Below or Equal to 2.5 mmol/L (45 mg/dl) (Yes/no)
ParticipantsIDegIDet
During the first 24 hours after birth — Yes2019
During the first 24 hours after birth — No6465
During the first 24 hours after birth — Unaddressed category21
Between 24 hours and 48 hours after birth — Yes45
Between 24 hours and 48 hours after birth — No7778
Between 24 hours and 48 hours after birth — Unaddressed category52

Adverse events

Collected over For IDeg; IDet : From first day of study drug administration until final follow-up (maximum 25 months) For IDeg infants; IDet infants:From delivery until follow-up (maximum 2 months) All adverse events are TEAEs. A TEAE is defined as event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomized treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg0/110 (0%)38/110 (34.5%)76/110 (69.1%)
IDet0/112 (0%)33/112 (29.5%)61/112 (54.5%)
IDegInf4/91 (4.4%)37/91 (40.7%)17/91 (18.7%)
IDetInf7/94 (7.4%)42/94 (44.7%)20/94 (21.3%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventIDegIDetIDegInfIDetInf
Neonatal respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/1100/1129/911/94
Premature babyPregnancy, puerperium and perinatal conditions0/1100/1129/913/94
Hypoglycaemia neonatalMetabolism and nutrition disorders0/1100/1125/914/94
Sepsis neonatalInfections and infestations0/1100/1125/911/94
Pre-eclampsiaPregnancy, puerperium and perinatal conditions6/1102/1120/910/94
Gestational hypertensionPregnancy, puerperium and perinatal conditions3/1106/1120/910/94
HypoglycaemiaMetabolism and nutrition disorders4/1106/1120/910/94
Jaundice neonatalPregnancy, puerperium and perinatal conditions0/1100/1121/915/94
Foetal distress syndromePregnancy, puerperium and perinatal conditions0/1100/1124/913/94
Threatened labourPregnancy, puerperium and perinatal conditions2/1104/1120/910/94
Most frequent other events
Showing 10 of 22
Most frequent other events
EventIDegIDetIDegInfIDetInf
NasopharyngitisInfections and infestations21/11023/1120/910/94
AnaemiaBlood and lymphatic system disorders22/11016/1120/910/94
Urinary tract infectionInfections and infestations11/1109/1120/910/94
HeadacheNervous system disorders8/11010/1120/910/94
HypoglycaemiaMetabolism and nutrition disorders0/1100/1126/918/94
HyperbilirubinaemiaHepatobiliary disorders0/1100/1122/917/94
DiarrhoeaGastrointestinal disorders8/1101/1120/911/94
Oedema peripheralGeneral disorders8/1101/1120/910/94
VomitingGastrointestinal disorders8/1106/1121/910/94
PolyhydramniosPregnancy, puerperium and perinatal conditions6/1108/1121/910/94

Baseline characteristics

FASall: included all randomised women contributed to the evaluation.

Age, Continuous
Age, Continuous(Years)IDegIDetTotal
Mean31.2 ± 5.2031.1 ± 5.2831.2 ± 5.23
Sex: Female, Male
Sex: Female, Male(Participants)IDegIDetTotal
Female111114225
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IDegIDetTotal
Hispanic or Latino241438
Not Hispanic or Latino87100187
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDegIDetTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American101
White106108214
More than one race000
Unknown or Not Reported459
09

Study locations

71 sites
  • Novo Nordisk Investigational Site
    Caba, C1180AAX, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1189AAS, Argentina
  • Novo Nordisk Investigational Site
    Caba, C1430CKE, Argentina
  • Novo Nordisk Investigational Site
    Córdoba, X5016KEH, Argentina
  • Novo Nordisk Investigational Site
    Mendoza, 5500, Argentina
  • Novo Nordisk Investigational Site
    Salta, 4400, Argentina
  • Novo Nordisk Investigational Site
    Blacktown, New South Wales 2148, Australia
  • Novo Nordisk Investigational Site
    Campbelltown, New South Wales 2560, Australia
  • Novo Nordisk Investigational Site
    St Leonards, New South Wales 2065, Australia
  • Novo Nordisk Investigational Site
    Ipswich, Queensland 4305, Australia
  • Novo Nordisk Investigational Site
    Elizabeth Vale, South Australia 5112, Australia
  • Novo Nordisk Investigational Site
    Box Hill, Victoria 3128, Australia
  • Novo Nordisk Investigational Site
    Parkville, Victoria 3052, Australia
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Wien, A 1170, Austria
  • Novo Nordisk Investigational Site
    Goiânia, Goias 74605-020, Brazil
  • Novo Nordisk Investigational Site
    Curitiba, Parana 80030-110, Brazil
  • Novo Nordisk Investigational Site
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, Sao Paulo 01228-200, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, Sao Paulo 05403-000, Brazil
  • Novo Nordisk Investigational Site
    Ribeirao Preto, 14049-900, Brazil
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2E1, Canada
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novo Nordisk Investigational Site
    St John's, Newfoundland and Labrador A1B 3V6, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • Novo Nordisk Investigational Site
    Cambridge, Ontario N1R 7L6, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6G 2V4, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M5T 3L9, Canada
  • Novo Nordisk Investigational Site
    PQ, Quebec G1L 3L5, Canada
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Aarhus N, 8200, Denmark
  • Novo Nordisk Investigational Site
    København ø, 2100, Denmark
  • Novo Nordisk Investigational Site
    Athens, 11521, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-11528, Greece
  • Novo Nordisk Investigational Site
    Larissa, GR-41110, Greece
  • Novo Nordisk Investigational Site
    Nea Efkarpia - Thessaloniki, GR-56403, Greece
  • Novo Nordisk Investigational Site
    Dublin 2, Ireland
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 7, Ireland
  • Novo Nordisk Investigational Site
    Galway, H91 YR71, Ireland
  • Novo Nordisk Investigational Site
    Petach Tikva, 49100, Israel
  • Novo Nordisk Investigational Site
    Rehovot, 76100, Israel
  • Novo Nordisk Investigational Site
    Milano, 20122, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Padova, 35143, Italy
  • Novo Nordisk Investigational Site
    Roma, 00189, Italy
  • Novo Nordisk Investigational Site
    Sant'Andrea Delle Fratte (PG), 06129, Italy
  • Novo Nordisk Investigational Site
    Torino, 10126, Italy
  • Novo Nordisk Investigational Site
    Ekaterinburg, 620028, Russian Federation
  • Novo Nordisk Investigational Site
    Kirov, 610014, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 101000, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199034, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410039, Russian Federation
  • Novo Nordisk Investigational Site
    Tomsk, 634050, Russian Federation
  • Novo Nordisk Investigational Site
    Ulianovsk, 432063, Russian Federation
  • Novo Nordisk Investigational Site
    Yoshkar-Ola, 424004, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Serbia
  • Novo Nordisk Investigational Site
    Barcelona, 08025, Spain
  • Novo Nordisk Investigational Site
    Bath, BA1 3NG, United Kingdom
  • Novo Nordisk Investigational Site
    Bradford, BD9 6RJ, United Kingdom
  • Novo Nordisk Investigational Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novo Nordisk Investigational Site
    High Wycombe, HP11 2TT, United Kingdom
  • Novo Nordisk Investigational Site
    Leeds, LS9 7TF, United Kingdom
  • Novo Nordisk Investigational Site
    Middlesbrough, TS4 3BW, United Kingdom
  • Novo Nordisk Investigational Site
    Norwich, NR4 7UQ, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX3 7LE, United Kingdom
  • Novo Nordisk Investigational Site
    Truro, TR1 3LJ, United Kingdom
10

References and documents

Publications

  • Mathiesen ER, Alibegovic AC, Corcoy R, Dunne F, Feig DS, Hod M, Jia T, Kalyanam B, Kar S, Kautzky-Willer A, Marchesini C, Rea RD, Damm P; EXPECT study group. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open-label, multinational, randomised, controlled, non-inferiority trial. Lancet Diabetes Endocrinol. 2023 Feb;11(2):86-95. doi: 10.1016/S2213-8587(22)00307-2. Epub 2023 Jan 6. Erratum In: Lancet Diabetes Endocrinol. 2023 May;11(5):e7. doi: 10.1016/S2213-8587(23)00096-7. Lancet Diabetes Endocrinol. 2023 Aug;11(8):e10. doi: 10.1016/S2213-8587(23)00169-9. PubMed 36623517 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2020, 36 months.

Results were first posted in Apr 2022, 1 year 4 months after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 36 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Dec 19, 2017
StartActual
Nov 22, 2017
Primary completionActual
Dec 17, 2020
CompletionActual
Dec 17, 2020
Results first posted
Apr 27, 2022
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03377699
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Nov 22, 2017
Primary completion
Dec 17, 2020
Completion
Dec 17, 2020
Results posted
Apr 27, 2022
Last update
Jan 20, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin degludec

Start the discussion